Thermo Fisher pairs a perfect 4-for-4 earnings beat streak and strong financial-health scores (Piotroski 9/9) with a price that has already reached the analyst target, so upside looks limited and the case is to hold rather than add.
Thesis pillars
- Consistent Earnings Beat Streak↑Improving
- Strong Financial Quality Piotroski→Stable
- Analyst Target Already Reached↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 26, 2026
Thermo Fisher Scientific Inc (TMO) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Sell if holding. Analyst target reached at $686.79 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum.
Thermo Fisher Scientific serves pharma, biotech, academic, and government customers through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Revenue comes from instruments, reagents,... Read more
Sell if holding. Analyst target reached at $686.79 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About Thermo Fisher Scientific Inc
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific operates through four business segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services—serving pharmaceutical and biotech companies, hospitals, clinical diagnostic labs, universities, government agencies, and environmental and industrial markets worldwide. The company employed approximately 125,000 colleagues at December 31, 2025, with 59,000 in the Americas, 44,000 in EMEA, and 22,000 in the Asia-Pacific region, distributing products through an approximately 14,000-person direct sales force plus electronic commerce and third-party distributors.
Life Sciences Solutions provides biosciences, genetic sciences, and bioproduction products to pharmaceutical and biotech research markets. Analytical Instruments covers chromatography and mass spectrometry, chemical analysis, and electron microscopy tools sold into pharmaceutical, environmental, semiconductor, and academic markets. Specialty Diagnostics serves clinical laboratories with diagnostic kits, immunodiagnostics reagents, microbiology culture media, and transplant diagnostics. Laboratory Products and Biopharma Services—which includes the Patheon pharma services brand and the PPD clinical research brand—bundles consumables and equipment procurement with outsourced drug development, manufacturing, and Phase I through Phase IV clinical trials. Revenue is historically stronger in the fourth quarter due to capital spending patterns among industrial, pharmaceutical, and government customers. The company's raw-materials policy states that no single supplier is material, though certain components may be sourced from sole or limited suppliers for quality assurance or regulatory requirements.
Show full overview
Thermo Fisher carries active environmental remediation obligations at two named Superfund sites: the Fair Lawn Wellfields site in New Jersey, where the company entered a consent decree with the USEPA in 2020 to finance a groundwater treatment plant that was constructed in 2025 and transferred to the Borough of Fair Lawn in January 2026; and the former Davis Landfill site in Smithfield, Rhode Island, governed by a 2021 consent decree amendment calling for an interim remedy expected to commence in 2026. Accrued environmental liabilities totaled $86 million at December 31, 2025, and the company acknowledges that future regulatory changes could increase remediation scope and cost.
See also: Healthcare · Diagnostics & Research
From Thermo Fisher Scientific Inc's most recent 10-K filing, extracted June 16, 2026.
Recent developments
No fresh coverage since Oct 22, 2026
Recent Developments — Thermo Fisher Scientific Inc
Latest news
- NEWS Thermo Fisher Scientific (TMO) Stock Faces A Q3 Earnings Disconnect - Yahoo Finance — Yahoo Finance Oct 22, 2026 neutral
- NEWS Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $701.64, Implies 2% Upside - TradingView — TradingView Oct 21, 2026 positive
- NEWS Why Is Thermo Fisher Scientific Stock Trading Higher Today? - Thermo Fisher Scientific (NYSE:TMO) - Benzinga — Benzinga Oct 21, 2026 positive
- NEWS Thermo Fisher stock gains on Q3 beat (update) (TMO:NYSE) - Seeking Alpha — Seeking Alpha Oct 21, 2026 positive
- NEWS Is Thermo Fisher Scientific Inc (TMO) Overvalued After Q3 Earnin - GuruFocus — GuruFocus Oct 21, 2026 neutral
Latest item Oct 22, 2026 · Generated 2026-11-18T11:52:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $686.79 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $646.57. Score 5.4/10, moderate confidence.
Analyst target $680.87 reached (−0.9% from $686.79); no take-profit level is published. Prior stop was $646.57. Stop-loss: $646.57.
Analyst target reached - limited upside remaining; Negative momentum.
Thermo Fisher Scientific Inc trades at a P/E of 36.5 (forward 24.7). TrendMatrix value score: 4.1/10. Verdict: Sell.
34 analysts rate TMO, with a consensus score of 4.1/5. 25 analysts publish price targets averaging $757.
What does Thermo Fisher Scientific Inc do?Thermo Fisher Scientific serves pharma, biotech, academic, and government customers through four segments: Life...
Thermo Fisher Scientific serves pharma, biotech, academic, and government customers through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Revenue comes from instruments, reagents, consumables, and outsourced drug manufacturing (Patheon/PPD), sold through ~14,000 direct sales staff plus distributors. The company employs approximately 125,000 globally.